Quanterix Corp
A maker of ultra-sensitive blood tests and tissue-imaging tools for biology research and diagnostics. Its Simoa platform detects single protein molecules in blood, powering tests like LucentAD Complete for Alzheimer's disease, while its PhenoCycler spatial biology systems map proteins inside intact tissue. Founded in 2007 by scientist David Walt, whose lab invented the single-molecule array technology, the company began life as Digital Genomics before renaming itself Quanterix. Simoa is short for "single molecule array," and the firm grew further by acquiring spatial-biology pioneer Akoya Biosciences in 2025.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Portolan Capital Management, LLC | 13G/APassive | 4.02% | 1.90M | Aug 14, 2026 |
| George McCabe | 13G/APassive | 4.02% | 1.90M | Aug 14, 2026 |
| First Eagle Investment Management, LLC | 13GPassive | 5.8% | 2.75M | Aug 6, 2026 |
| FIRST EAGLE SMALL CAP OPPORTUNITY FUND | 13GPassive | 5.1% | 2.42M | Aug 6, 2026 |
| Ameriprise Financial, Inc. | 13G/APassive | 7.5% | 3.54M | May 15, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Telegraph Hill Partners III, L.P. | 13GPassive | 5.4% | 2.50M | Nov 19, 2025 |
| THP III Affiliates Fund, LLC | 13GPassive | 5.4% | 2.50M | Nov 19, 2025 |
| Telegraph Hill Partners III Investment Management, LLC | 13GPassive | 5.4% | 2.50M | Nov 19, 2025 |
| Telegraph Hill Partners Management Company, LLC | 13GPassive | 5.4% | 2.50M | Nov 19, 2025 |